Evidence map›Paper›PMID 35071938›Full record

ReviewAIMS microbiology2021

Nanotechnology-based approaches in the fight against SARS-CoV-2.

Alrayan Abass Albaz, Misbahuddin M Rafeeq, Ziaullah M Sain, Wael Abdullah Almutairi, Ali Saeed Alamri, Ahmed Hamdan Aloufi, Waleed Hassan Almalki, Mohammed Tarique

Abstract readReview
In one paragraph

Review in AIMS microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alrayan Abass AlbazMolecular Medicine Genetics, Department of Oncology and Human Metabolism, the Medical School, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom.
Misbahuddin M RafeeqDepartment of Pharmacology, Faculty of Medicine, Rabigh. King Abdulaziz University. Jeddah, 21589, KSA.
Ziaullah M SainDepartment of Microbiology, Faculty of Medicine, Rabigh. King Abdulaziz University, Jeddah, KSA 21589.
Wael Abdullah AlmutairiDepartment of Respiratory Services, Ministry of National Guard Hospital and Health Affairs (MNGHA) P.O. box 22490, kingdom of Saudi Arabia.
Ali Saeed AlamriMolecular Pathology Lab Department of Pathology and Laboratory Medicine, Ministry of National Guard Hospital and Health Affairs (MNGHA), P.O. box 22490, Kingdom of Saudi Arabia.
Ahmed Hamdan AloufiDepartment of Pathology and Laboratory Medicine, Ministry of National Guard-Health Affairs P.O. box 22490, Kingdom of Saudi Arabia.
Waleed Hassan AlmalkiDepartment of Pharmacology and Toxicology, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
Mohammed TariqueCenter for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi-110025, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic caused by highly-infectious virus namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in infection of millions of individuals and deaths across the world. The need of an hour is to find the innovative solution for diagnosis, prevention, and cure of the COVID-19 disease. Nanotechnology is emerging as one of the important tool for the same. In the present review we discuss the applications of nanotechnology-based approaches that are being implemented to speed up the development of diagnostic kits for SARS-CoV-2, development of personal protective equipments, and development of therapeutics of COVID-19 especially the vaccine development.

Indexed as

COVID-19diagnosticsnanomaterialsnanostructuresnanotechnologySARS-CoV-2vaccine

Identifiers

PMID35071938
PMCPMC8712532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.